Opioid Use Disorder: Clinical Trials

48 trials for Opioid Use Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

25 completed, 9 recruiting, 5 active not recruiting, 3 terminated. 48 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 148Completed 25, Recruiting 9, Active not recruiting 5, Terminated 3, Not yet recruiting 2, Unknown 2, Withdrawn 2
Phase 27Completed 4, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1

Follow Opioid Use Disorder: new trials by email Literature Review of Opioid Use Disorder trials Research Report on Opioid Use Disorder

Trials (filtered) newest first · largest first

All 48 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder
Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo - Opioid Use Disorder, Opioid Withdrawal
Phase 1 / Phase 2Not yet recruitingClive Michelsen602027-07-012026-10-13
Cannabis Effects on Opioid Self-Administration
Cannabis, Placebo Cannabis, Intranasal Opioid Agonist - Opioid Use Disorder, Cannabis Use
Phase 1Not yet recruitingShanna Babalonis, PhD302026-11-302026-10-14
Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder
[11C]OMAR - Opioid Use Disorder, OAT
Phase 1RecruitingYale University1102026-10-012026-10-02
iSTEP-N 101b: Pharmacokinetics and Safety Study of iSTEP-N Implant vs Monthly Vivitrol in Healthy Volunteers
Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg - Opioid Use Disorder
Phase 1Active not recruitingAkyso Therapeutics, LLC212026-07-252026-11-12
Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder
Transcranial Direct Current Stimulation (tDCS) - Opioid Use Disorder
Phase 1RecruitingUniversity of Minnesota402026-02-042026-07-06
Autonomous Digital CBT Intervention for Opioid Use Disorder in Individuals With Co-Occurring Internalizing Disorders
NEAT-O program - Opioid Use Disorder, Anxiety
Phase 1Active not recruitingUniversity of Minnesota172025-08-212026-02-12
Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder
Guanfacine pharmacotherapy, Mindfulness Oriented Recovery Enhancement (MORE) - Mindfulness, Guanfacine
Phase 1RecruitingRutgers, The State University of New Jersey2242025-07-152025-08-08
Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
Telemedicine Buprenorphine Treatment - Opioid Use Disorder
Phase 1RecruitingBoulder Care2502025-06-102025-09-11
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects
LUCEMYRA (lofexidine) tablets - Opioid Withdrawal (Disorder), Opioid Use Disorder
Phase 1WithdrawnUSWM, LLC (dba US WorldMeds)2025-06-012025-08-01
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
Psilocybin - Opioid Use Disorder
Phase 1RecruitingYale University122025-05-282026-07-07
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine
BI 1356225, Placebo - Opioid Use Disorder
Phase 1TerminatedBoehringer Ingelheim122025-01-272026-07-31
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
Tezampanel, Placebo - Opioid Use Disorder
Phase 1RecruitingProniras Corporation402024-10-162026-09-17
Cannabis and Opioid Use Disorder
Inhaled vaporized cannabis, Intransal opioid - Opioid Use Disorder
Phase 1RecruitingShanna Babalonis, PhD152024-09-102026-06-18
Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults
BIOPIN-6 Active Implant with Naltrexone, BIOPIN-6 Placebo Implant - Opioid Use Disorder
Phase 1CompletedAkyso Therapeutics, LLC162024-06-242026-04-28
Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder
Buprenorphine - Opioid Use Disorder
Phase 1CompletedBrigham and Women's Hospital182024-06-042025-10-23
Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).
AZD4041, Itraconazole, Buprenorphine - Opioid Use Disorder
Phase 1TerminatedAstraZeneca152024-05-132025-03-26
Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System
[11C]-PHNO, Calcitriol, Placebo Control - Opioid Use Disorder
Phase 1CompletedYale University52024-03-132025-11-14
SafeMedWaste At-Home, Environmentally-Friendly Opioid Disposal Kit for Orthopedic Post-Operative Surgical Patients to Reduce Opioids Available for Diversion
SafeMedWaste - Opioid Use Disorder
Phase 1UnknownSafeMedWaste, Inc.3002024-02-012024-01-22
Hyperbaric Oxygen Treatment (HBOT) During Methadone Tapering
Hyperbaric Oxygen Treatment Full, Hyperbaric Oxygen Treatment Sham, Hyperbaric Oxygen Treatment Partial Pressure - Opioid Use Disorder
Phase 1CompletedWashington State University252023-12-042026-06-04
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
Placebo, Auvelity - Addiction, Opioid Use
Phase 1 / Phase 2CompletedVirginia Commonwealth University182023-09-182026-08-19

Showing 20 of 48. Sign in to see all of them.

Narrower conditions

Opioid-Related Disorders (48)  ·  Substance-Related Disorders (4)  ·  Behavior, Addictive (2)  ·  Chronic Pain (2)  ·  Marijuana Abuse (2)  ·  Anxiety Disorders (1)  ·  Chemically-Induced Disorders (1)  ·  Depression (1)  ·  Depressive Disorder (1)  ·  Digestive System Diseases (1)  ·  Heroin Dependence (1)  ·  Hyperalgesia (1)  ·  Mental Disorders (1)  ·  Motor Activity (1)  ·  Opiate Overdose (1)

Broader conditions

Narcotic-Related Disorders (48)  ·  Chemically-Induced Disorders (47)  ·  Mental Disorders (47)  ·  Substance-Related Disorders (44)  ·  Behavior (4)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Compulsive Behavior (2)  ·  Disease Attributes (2)  ·  Impulsive Behavior (2)  ·  Neurologic Manifestations (2)  ·  Pathologic Processes (2)  ·  Signs and Symptoms (2)  ·  Behavioral Symptoms (1)  ·  Chronic Disease (1)  ·  Drug Misuse (1)

Interventions

Buprenorphine (4)  ·  Buprenorphine, Naloxone Drug Combination (4)  ·  Naltrexone (4)  ·  Morphine (3)  ·  4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (2)  ·  Cannabidiol (2)  ·  Naloxone (2)  ·  Oxytocin (2)  ·  Psilocybin (2)  ·  carfentanil (2)  ·  lofexidine (2)  ·  3-alpha-Hydroxysteroid Dehydrogenase (B-Specific) (1)  ·  3-chloro-4-(4-((2-(3-pyridyl)pyrrolidin-1-yl)methyl)phenoxy)benzamide (1)  ·  ASP8062 (1)  ·  Analgesics, Opioid (1)

Sponsors

Yale University (5)  ·  Indivior Inc. (4)  ·  New York State Psychiatric Institute (3)  ·  Akyso Therapeutics, LLC (2)  ·  Astellas Pharma Global Development, Inc. (2)  ·  AstraZeneca (2)  ·  Shanna Babalonis, PhD (2)  ·  University of Minnesota (2)  ·  Virginia Commonwealth University (2)  ·  Boehringer Ingelheim (1)  ·  Boulder Care (1)  ·  Brigham and Women's Hospital (1)  ·  Brown University (1)  ·  Center for Social Innovation, Massachusetts (1)  ·  Cerevel Therapeutics, LLC (1)

Countries

United States (47)

Top investigators

Anahita Bassir Nia, MD (2)  ·  Shanna Babalonis, PhD (2)  ·  Adam Bisaga, MD (1)  ·  Andrea Baron, MPH (1)  ·  Annabelle Belcher, PhD (1)  ·  Aynur Unalp-Arida, MD, PhD (1)  ·  Cecilia L Bergeria, PhD (1)  ·  Christopher S Stauffer, MD (1)  ·  Debra Kelsh, MD (1)  ·  Elizabeth Evans, MD (1)  ·  Frederick G Moeller (1)  ·  Frederick G Moeller, MD (1)  ·  Gustavo Angarita, MD, MHS (1)

Results publications

PMID 10870744, PMID 11165371, PMID 11786502, PMID 14621285, PMID 15647484, PMID 15800228, PMID 16508405, PMID 17123731, PMID 17237664, PMID 17433624, PMID 17635557, PMID 17853395, PMID 18294378, PMID 18362258, PMID 18378801, PMID 18419722, PMID 18619874, PMID 18774343, PMID 19409861, PMID 19789074, PMID 20031953, PMID 20086062, PMID 21029787, PMID 21148579, PMID 21249671, PMID 21412914, PMID 21765969, PMID 22336864, PMID 22494121, PMID 22898544, PMID 24661411, PMID 24867013, PMID 25221944, PMID 25418676, PMID 25872113, PMID 25957198, PMID 26029937, PMID 26987082, PMID 27407096, PMID 28074005, PMID 28106092, PMID 28119481, PMID 28409480, PMID 28767350, PMID 29671994, PMID 29769209, PMID 30325859, PMID 30325862, PMID 31089778, PMID 31404020

NIH funding

U54DA037842 (2), UG3DA051392 (2), 1UG3DA061620 (1), 4UH3DA052166-02 (1), 5UG1DA050207 (1), 5UG3DA048338-02 (1), IK2CX002286 (1), K12DA000167 (1), P20GM130414 (1), R01DA054347 (1), R01DA063712 (1), R01DK132709 (1), R21DA046030 (1), R21DA052864 (1), R43DA057750 (1)